Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7588033 | 0.93 | EPHX2 (0.40) | TSHRCA2CA1CYP2D6EPHX2 | |
| SCHEMBL27008556 | 0.89 | HDAC3 (0.37) | TSHRCA2CA1CYP2D6EPHX2 | |
| SCHEMBL7588140 | 0.89 | CYP2D6 (0.38) | TSHRCA2CA1CYP2D6EPHX2 | |
| SCHEMBL10425792 | 0.83 | TSHR (0.56) | TSHRCA2CA1MEN1KMT2A | |
| SCHEMBL8237941 | 0.80 | CA1 (0.50) | TSHRCA2CA1EPHX2MEN1 | |
| SCHEMBL27730932 | 0.79 | CYP1A2 (0.50) | TSHRCA2CA1MEN1GAA | |
| SCHEMBL29100702 | 0.78 | HDAC3 (0.39) | CYP2D6EPHX2MEN1GAAKMT2A | |
| SCHEMBL29100706 | 0.78 | HDAC3 (0.39) | CYP2D6EPHX2MEN1GAAKMT2A | |
| SCHEMBL396125 | 0.78 | CYP2D6 (0.40) | TSHRCA2CA1CYP2D6EPHX2 | |
| SCHEMBL18207130 | 0.78 | CYP2D6 (0.47) | CA2CA1CYP2D6MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492550-B2 | INHIBITORS OF THE CYTOSOLIC PHOSPHOLYPASE A2 ENZYMES | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-10 | — | — | US | disclosed |
| WO-2002048331-A2 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLTRANSFERASES AND ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND 'UNNATURAL' UDP- AND NUCLEOTIDE SUGARS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2002-06-20 | — | — | WO | disclosed |
| US-20020068722-A1 | Alpha-substituted thio,-oxo trifluoromethylketones as phospholipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068722-A1 | Alpha-substituted thio,-oxo trifluoromethylketones as phospholipase inhibitors | PLA2G4B, PLA2G4A, PLA2G1B | TSHR 2709/4885CA2 898/4885CA1 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.